BLEOMYCIN
Liver Metastases
Institute of Oncology LjubljanamixturePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
36 Active assets in the Liver Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sun Yat-sen University | Phase 3 | BB |
Irinotecan Kamya Sankar | Phase 3 | BB |
FLUOROURACILUM Sun Yat-sen University | Phase 3 | BB |
Calcium folinate pentahydrate Fudan University | Phase 3 | BB |
Ipilimumab Vastra Gotaland Region | Phase 3 | B |
View all 50 →
Same molecule, other indications
BLEOMYCIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →